Gluconic Acid

Gluconic Acid

SCHEMBL473633

O.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Fe+2]

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.87
PDE4A P27815 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.50
USP2 O75604 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
OR51E2 Q9H255 1/20 0.39
KDM4E B2RXH2 2/20 0.37
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CA4 P22748 2/20 0.31
TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gluconic Acid SCHEMBL1565178 1.00 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL721131 1.00 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL19585112 1.00 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL22442432 1.00 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL7265130 1.00 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL9456606 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL161222 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL35424 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL3768836 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL23566696 0.95 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024258187-A1 COMPOSITION FOR STRENGTHENING HAIR ROOTS COMPRISING METAL-PHENOLIC COMPLEX AND MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO claimed
CN-116359391-A Detection method of sulfonamide antibiotics in soil and sample treatment method thereof 浙江省农业科学院 2023-06-30 CN claimed
US-11597863-B2 Methods of cementing a wellbore BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2023-03-07 US claimed
WO-2020190956-A1 METHODS OF CEMENTING A WELLBORE BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2020-09-24 WO claimed
US-20200299563-A1 METHODS OF CEMENTING A WELLBORE BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2020-09-24 US claimed
WO-2024258193-A1 METAL-PHENOL COMPLEX AND DYEING COMPOSITION COMPRISING MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO disclosed
WO-2024258183-A1 SKIN SOOTHING OR ANTI-INFLAMMATORY COMPOSITION COMPRISING METAL-PHENOLIC COMPLEX AND MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO disclosed
WO-2024258187-A1 COMPOSITION FOR STRENGTHENING HAIR ROOTS COMPRISING METAL-PHENOLIC COMPLEX AND MELANIN OR PRECURSOR THEREOF 코스맥스 주식회사 2024-12-19 WO disclosed
WO-2024258190-A1 HAIR DYE COMPOSITION FOR PREMATURE GRAY HAIR AND METHOD FOR PREPARING SAME 코스맥스 주식회사 2024-12-19 WO disclosed
CN-116359391-A Detection method of sulfonamide antibiotics in soil and sample treatment method thereof 浙江省农业科学院 2023-06-30 CN disclosed
US-11597863-B2 Methods of cementing a wellbore BAKER HUGHES OILFIELD OPERATIONS LLC (US) 2023-03-07 US disclosed
CN-115429899-A Method for producing reagent and reagent produced by the production method 牛尾电机(苏州)有限公司 2022-12-06 CN disclosed
WO-2007035886-A1 NATURAL BIODEGRADABLE MATRICES AND USES THEREOF SURMODICS, INC. (US) 2007-03-29 WO disclosed
US-20070071792-A1 In VIVO formed matrices including natural biodegradale polysaccharides and ophthalmic uses thereof SURMODICS MD, LLC 2007-03-29 US disclosed
WO-2007035865-A1 COATINGS AND ARTICLES INCLUDING NATURAL BIODEGRADABLE POLYSACCHARIDES SURMODICS, INC. (US) 2007-03-29 WO disclosed
US-20070065484-A1 In situ occlusion using natural biodegradable polysaccharides SURMODICS MD, LLC 2007-03-22 US disclosed
US-20070065481-A1 Coatings including natural biodegradable polysaccharides and uses thereof SURMODICS MD, LLC 2007-03-22 US disclosed
US-20070065483-A1 In vivo formed matrices including natural biodegradable polysaccharides and uses thereof SURMODICS MD, LLC 2007-03-22 US disclosed
US-20070065482-A1 Articles including natural biodegradable polysaccharides and uses thereof SURMODICS MD, LLC 2007-03-22 US disclosed
US-20050154146-A1 Process for the preparation of iron ion containing water-absorbent polymers with low residual monomer content DOW GLOBAL TECHNOLOGIES INC. 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070065481-A1 Coatings including natural biodegradable polysaccharides and uses thereof FUT6, FUT5, CD44 LMNA 3532/4885PDE4A 2149/4885L3MBTL1 3141/4885
US-20070065482-A1 Articles including natural biodegradable polysaccharides and uses thereof CD44, FUT6, FGF23 LMNA 3763/4885PDE4A 1284/4885L3MBTL1 3118/4885
US-20070065483-A1 In vivo formed matrices including natural biodegradable polysaccharides and uses thereof CD44, ADAMTS4, BMP2 LMNA 1063/4885PDE4A 1101/4885L3MBTL1 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.